The clinical trial PREFERE aims to recruit 7600 patients with "early intermediate" prostate cancer.
The goal is to confirm noninferiority of cancer-specific survival after external-beam radiotherapy, permanent seed implantation, or active surveillance compared with radical prostatectomy.
Wiegel T, Stöckle M, Bartkowiak D. Are you the author?
Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany; Department of Urology, University Hospital Homburg/Saar, Homburg, Germany.
Reference: Eur Urol. 2014 Sep 27. pii: S0302-2838(14)00911-7.